Conditional marketing authorisation
Sector Deep DivesAn EU authorisation granted on less complete evidence where the medical need is unmet, subject to obligations to complete confirmatory studies.
Also written: conditional authorisation, conditional approval
It exists because waiting for a full evidence package can cost patients years in areas where nothing works. The medicine is authorised on data that would not normally suffice, and the company carries specific obligations to run the studies that would have supported a standard authorisation.
It is renewed periodically rather than granted once. If the confirmatory evidence arrives and satisfies the regulator, it converts to a standard authorisation. If it does not, the authorisation can be withdrawn.
For a model the effect runs both ways. Revenue starts earlier, which is worth real value because so much of a drug's net present value sits in its early protected years. But the confirmatory trial cost stays in the forecast rather than disappearing at launch, and a probability of failing to convert has to be carried alongside the revenue line.
The reliable error is treating it as permanent. Dropping the conversion risk and the confirmatory cost takes a live, disclosed risk out of the valuation and replaces it with silence, which is a different thing from an optimistic assumption because nobody can argue with it.
Worked example
An oncology asset receives a conditional authorisation and begins selling two years earlier than a standard route would have allowed.
A model that books the earlier revenue and also removes the remaining trial spend and the conversion risk has taken the benefit of the mechanism twice and its cost not at all.